Oregon
How Association for Molecular Pathology v. Myriad Genetics, Inc. applies in Oregon: state-specific rules, key cases, and bar exam notes for Intellectual Property (Patent Law).
Oregon law follows the principles set forth in Association for Molecular Pathology v. Myriad Genetics, which emphasizes that naturally occurring genes cannot be patented. The Oregon Courts would likely analyze patent eligibility similarly to federal courts, focusing on the patentability of isolated DNA sequences.
In Oregon, a natural product or law of nature cannot be patented. Isolated genes that are naturally occurring do not meet the criteria for patentable subject matter as established by the state case law and federal principles.
The court upheld that educational institutions cannot trademark naturally occurring materials used in their research, aligning with the principles set forth in Myriad.
The appellate court ruled that patent applications for naturally derived substances must demonstrate significant human intervention to qualify as patentable, resonating with the ruling in Myriad.
The University’s claims related to gene therapy were denied based on Myriad's principles of non-patentability of naturally occurring genes and sequences.
Oregon's approach aligns closely with the federal standard articulated in Myriad, emphasizing that both federal and state law reject the patentability of natural gene sequences. However, state courts may impose additional scrutiny on specific applications of biotechnology relevant to Oregon's unique regulatory environment.
Understanding the implications of Myriad is crucial for the Oregon Bar Exam, especially in relation to patent law as it covers the principles of patent eligibility and its effects on biotechnological innovations.